OXURION NV (OXUR.BR)

BE0003846632 - Common Stock

0.0001  0 (0%)

Fundamental Rating

0

OXUR gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 77 industry peers in the Biotechnology industry. OXUR may be in some trouble as it scores bad on both profitability and health. OXUR does not seem to be growing, but still is valued expensively.



0

1. Profitability

1.1 Basic Checks

In the past year OXUR has reported negative net income.
OXUR had a negative operating cash flow in the past year.
In the past 5 years OXUR always reported negative net income.
OXUR had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

OXUR has a worse Return On Assets (-235.40%) than 88.89% of its industry peers.
Industry RankSector Rank
ROA -235.4%
ROE N/A
ROIC N/A
ROA(3y)-166.79%
ROA(5y)-122.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of OXUR (15.15%) is comparable to the rest of the industry.
OXUR's Gross Margin has declined in the last couple of years.
OXUR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 15.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-31.43%
GM growth 5Y-28.06%

0

2. Health

2.1 Basic Checks

OXUR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OXUR has been increased compared to 1 year ago.
Compared to 5 years ago, OXUR has more shares outstanding
OXUR has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -14.82, we must say that OXUR is in the distress zone and has some risk of bankruptcy.
OXUR has a Altman-Z score of -14.82. This is amonst the worse of the industry: OXUR underperforms 90.28% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.82
ROIC/WACCN/A
WACC5.63%

2.3 Liquidity

A Current Ratio of 0.40 indicates that OXUR may have some problems paying its short term obligations.
OXUR has a worse Current ratio (0.40) than 95.83% of its industry peers.
A Quick Ratio of 0.40 indicates that OXUR may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.40, OXUR is doing worse than 94.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.4
Quick Ratio 0.4

0

3. Growth

3.1 Past

OXUR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.34%, which is quite impressive.
Looking at the last year, OXUR shows a very negative growth in Revenue. The Revenue has decreased by -51.18% in the last year.
Measured over the past years, OXUR shows a very negative growth in Revenue. The Revenue has been decreasing by -41.99% on average per year.
EPS 1Y (TTM)66.34%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q93.75%
Revenue 1Y (TTM)-51.18%
Revenue growth 3Y-46.77%
Revenue growth 5Y-41.99%
Revenue growth Q2Q-30.77%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

OXUR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

OXUR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

OXURION NV

EBR:OXUR (4/24/2024, 7:00:00 PM)

0.0001

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap901.48K
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -235.4%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 15.15%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.4
Quick Ratio 0.4
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)66.34%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-51.18%
Revenue growth 3Y-46.77%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y